Novo Nordisk faces new GLP-1 rival as Eli Lilly's triple agonist sets weight-loss record

Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a...